STOCK TITAN

Kura Oncology Insider Notice: 8,891 Shares to Sell via Morgan Stanley

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Kura Oncology (KURA) Form 144 notice states that an individual proposes to sell 8,891 shares of common stock on or about 09/29/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports an aggregate market value of $80,463.55 and total shares outstanding of 87,015,518. The shares were acquired as RSUs from the issuer on 09/27/2025 and are listed as payable on 09/29/2025. The filer reports no sales of the issuer's securities in the past three months and includes the standard signature representation that no undisclosed material adverse information is known.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider sale is small relative to outstanding shares and market capitalization, indicating limited market impact.

The proposed sale of 8,891 shares valued at $80,463.55 represents a de minimis portion of Kura Oncology's 87,015,518 outstanding shares. The sale follows RSU acquisition on 09/27/2025, suggesting a routine post-vesting disposition rather than a large liquidation. No other sales in the past three months were reported, reducing likelihood of a pattern of insider selling. For investors, this filing is procedural and not materially informative about company fundamentals.

TL;DR: Filing complies with Rule 144 disclosure; transaction appears routine and includes required attestation.

The notice discloses the broker, proposed sale date, and acquisition details (RSU on 09/27/2025) consistent with Rule 144 requirements. The absence of prior three-month sales and the inclusion of the standard representation regarding material non-public information indicate adherence to disclosure norms. There is no indication of procedural issues or governance irregularities from the information provided.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does KURA's Form 144 disclose about the proposed sale?

The notice discloses a proposed sale of 8,891 common shares on 09/29/2025 via Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $80,463.55.

How were the shares being sold acquired?

The shares were acquired as RSUs from the issuer on 09/27/2025 and are listed for sale with payment date 09/29/2025.

Did the filer report any other sales in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Which broker is handling the proposed sale?

The broker named in the filing is Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY.

How large is the proposed sale relative to outstanding shares?

The proposed sale of 8,891 shares compares to 87,015,518 shares outstanding, representing a negligible percentage of the share count.